Humana · Daa Pangenotypic Epclusa · US health-plan appeal rights

Daa Pangenotypic Epclusa denied as not FDA-approved for this use by Humana?

Q: How long do I have to appeal a Humana Daa Pangenotypic Epclusa denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Off-label use is widespread in medicine. If the literature and a recognised specialty-society guideline support the use, plans frequently approve on appeal — especially for cancer, cardiology, and rare disease.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Humana typically requires

Humana's specific coverage criteria for daa pangenotypic epclusa are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: Humana Drug List / Part D Formulary; Humana Medical Coverage Policy Hepatitis C

The Humana angle on Daa Pangenotypic Epclusa

## Why Humana Issued a Not-FDA-Approved Denial for Epclusa

Epclusa (sofosbuvir/velpatasvir) holds FDA approval for the treatment of chronic hepatitis C in adults and eligible pediatric patients, as described in its current prescribing label. A "not-FDA-approved" denial from Humana for a standard, on-label use of Epclusa is almost certainly a coding or administrative error — either the indication submitted did not match the label's language, the patient's age or weight profile was not clearly documented, or the prior-authorization form referenced an off-label use.

This type of denial is one of the most straightforward to reverse on appeal because the FDA-approval status of Epclusa is a matter of public record. The appeal strategy is to supply the specific label language confirming the approved indication, link it to the patient's documented diagnosis, and demonstrate that the prescriber's order falls squarely within approved use.

## Federal Appeal Framework

ACA Section 2719 / external review: Non-grandfathered plans must offer independent external review by an accredited IRO after internal appeals are exhausted. The standard deadline is approximately four months from the denial notice; verify the exact date on your Explanation of Benefits. Expedited external review (approximately 72 hours) is available when delay would seriously jeopardize health.
ERISA Section 503: Employer-sponsored plans must provide a full-and-fair review and must disclose the specific criteria cited in the denial.

## Concrete Appeal Steps and Timeline

1. Request the full denial letter identifying which "not-FDA-approved" determination was made and which policy provision was applied. 2. Retrieve the current FDA-approved prescribing information for Epclusa directly from the FDA's DailyMed database or the manufacturer. 3. File a Level 1 internal appeal within the plan-stated deadline, attaching the prescribing label excerpt confirming approval and the prescriber's attestation of on-label use. 4. If internal appeal is denied, escalate to external review within the deadline on your denial notice.

## Documentation to Gather

Diagnosis confirmation: Hepatitis C diagnosis with genotype, viral load, and the clinical note linking the patient's presentation to the approved indication in the Epclusa label.
Label excerpt: The relevant section of the FDA-approved prescribing information confirming the indication, age/weight eligibility, and any other approval parameters.
Prescriber attestation: A letter from the treating provider confirming the order is within the FDA-approved indication and explaining why this patient meets the label criteria.
Prior-treatment history: Documentation supporting that the prescribed use is consistent with the treatment pathway described in the applicable AASLD/IDSA hepatitis C guidance.

## Criteria-Mapping Structure

Side-by-side: in the left column, list the approval language from the Epclusa label and Humana's coverage policy requirements; in the right column, cite the corresponding chart documentation. The goal is to make it unambiguous that the prescribed use is on-label and that the "not-FDA-approved" determination was applied in error.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Humana appeals

Other denial reasons for Humana Daa Pangenotypic Epclusa

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.